.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Please enable Javascript to use all features and improve your user experience.

Dr. André Schreiber

Münster / DE

University of Muenster

Speaker

25/03/2024
Poster
P 068
Zapnometinib – A host targeted MEK1/2-inhibitor with broad anti-SARS-CoV-2 activity, strong synergism with licensed drugs and a high barrier towards emergence of resistance
Antiviral therapy and resistance

Further involvements

25/03/2024
Poster
P 068
Zapnometinib – A host targeted MEK1/2-inhibitor with broad anti-SARS-CoV-2 activity, strong synergism with licensed drugs and a high barrier towards emergence of resistance
Antiviral therapy and resistance
25/03/2024
Poster
P 357
Role of the 90 kDa ribosomal S6 kinases 1-3 during the IAV replication cycle
Virus replication strategies
25/03/2024
Poster
P 225
SARS-CoV-2 infection depends on the p90 ribosomal S6 kinases RSK1 and RSK3
Host cell factors